RBC Life Sciences, Inc.
RBCL
$0.0001
$0.000.00%
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | 5.41M | 6.19M | 5.36M | 7.16M | 7.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.41M | 6.19M | 5.36M | 7.16M | 7.51M |
| Cost of Revenue | 2.28M | 2.69M | 2.31M | 3.11M | 3.23M |
| Gross Profit | 3.12M | 3.50M | 3.05M | 4.05M | 4.28M |
| SG&A Expenses | 4.14M | 3.67M | 3.73M | 4.02M | 4.20M |
| Depreciation & Amortization | 129.90K | 131.00K | 94.20K | 122.70K | 160.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.55M | 6.50M | 6.14M | 7.25M | 7.59M |
| Operating Income | -1.14M | -305.40K | -776.60K | -88.20K | -78.00K |
| Income Before Tax | 562.00K | -325.60K | -797.90K | -110.60K | -101.50K |
| Income Tax Expenses | 231.30K | -79.90K | -247.90K | -15.90K | 22.20K |
| Earnings from Continuing Operations | 330.70K | -245.60K | -550.00K | -94.60K | -123.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 330.70K | -245.60K | -550.00K | -94.60K | -123.60K |
| EBIT | -1.14M | -305.40K | -776.60K | -88.20K | -78.00K |
| EBITDA | -1.01M | -156.00K | -663.70K | 40.50K | 82.80K |
| EPS Basic | 0.15 | -0.11 | -0.25 | -0.04 | -0.06 |
| Normalized Basic EPS | -0.32 | -0.09 | -0.23 | -0.03 | -0.03 |
| EPS Diluted | 0.15 | -0.11 | -0.25 | -0.04 | -0.06 |
| Normalized Diluted EPS | -0.32 | -0.09 | -0.23 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 2.21M | 2.21M | 2.21M | 2.21M | 2.21M |
| Average Diluted Shares Outstanding | 2.21M | 2.21M | 2.21M | 2.21M | 2.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
